NeuroStar transcranial magnetic stimulation (TMS) therapy has showed effective outcome and adherence rates in patients with major depressive disorder.
The open-label study, conducted at 40 clinical practices in the US, enrolled 99 patients with the condition.
Pateients experienced an improvement in symptoms, complete symptom resolution and average reduction in their depression symptom score.
TMS Center of New England medical director Karl Lanocha said the data provides evidence that TMS therapy has a positive impact on patients with major depression.
NeuroStar TMS Therapy is a non-systemic and non-invasive form of neuromodulation.
It stimulates nerve cells in an area of the brain that has been linked to depression by delivering highly focused MRI-strength magnetic field pulses.
The adverse affects related to treatment were scalp pain or discomfort and risk of seizures.